Announcements
- Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
As of last trade Catalyst Pharmaceuticals Inc (CN2:MUN) traded at 15.37, -0.45% below its 52-week high of 15.44, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.37 |
---|---|
High | 15.37 |
Low | 15.37 |
Bid | 15.44 |
Offer | 15.80 |
Previous close | 15.33 |
Average volume | 25.33 |
---|---|
Shares outstanding | 118.12m |
Free float | 110.78m |
P/E (TTM) | 31.39 |
Market cap | 2.00bn USD |
EPS (TTM) | 0.5384 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 07:04 BST.
More ▼